Studies
Inactive
All Studies
Expand your treatment options and enhance your practice by integrating clinical trials. Gain access to a diverse portfolio of studies, sourced from over 20 industry sponsors, and broaden the care you can offer your community. Our tailored approach to trial matching ensures your patients are connected with studies that meet their specific needs, allowing them to explore the latest advancements in care and discover how clinical trials can directly benefit their health journey. Find available trials nearby and empower your patients with access to cutting-edge treatments.
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.
Advanced MTAP-null Solid Tumors
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
